Management

Zoltan Kiss, Ph.D. - He founded ZK Statin Plus biotechnological company in 2021 for which now he serves as the President and CEO. This family-owned company is based, for the most part, on his work using a human non-toxic protein, ZKPr, to investigate various aspects of metabolism in obese mice. Along those investigations, he and collaborators found beneficial effects of ZKPr in statin treated obese mice that are viewed significant enough to merit formation of a company for the purpose of commercializing these important findings affecting, in principle, all obese statin users.

*About the Founder: Zoltan Kiss, Ph.D., had an extensive academic research career before founding and leading several biotechnological companies. Until 2004, he was Professor and Section Leader at the University of Minnesota. Prior to that, he was a Senior Investigator at the National Cancer Institute (4 years) and held several faculty positions in the U.S. and Europe. Dr. Kiss holds a Ph.D. degree, and his research so far has resulted in 114 peer-reviewed articles and 27 issued international patents as well as 5 filed patent applications on the treatments of cancer cachexia, wounds, and various metabolic disorders including specific treatment of excess visceral fat. Most recently, Dr. Kiss has been focusing on five projects, in each case the goal being to prepare them for phase 1 human trials: (1) The normalizing effect of ZKPr on excess visceral obesity, (2) the combined effects of statin and ZKPr on metabolism, (3) using ZKPr to prevent cancer cachexia, (4) using a heterocyclic compound to stabilize body weight for periods when treatments with weight loss drugs are stopped, and (5) using a heterocyclic compound to reduce/prevent cancer cachexia.